Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies.

Tissue factor (TF) is a cell surface protein that plays a role in blood clotting but is also commonly expressed in many cancers. Recent research implicated TF in cancer proliferation, metastasis, angiogenesis, and immune escape. Therefore, TF can be considered a viable therapeutic target against cancer.

Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images.

Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are limited. Here, we introduce HistoTME, a novel weakly supervised deep learning approach to infer the tumor microenvironment (TME) composition directly from histopathology images of NSCLC patients.

Masked Image Modeling Meets Self-Distillation: A Transformer-Based Prostate Gland Segmentation Framework for Pathology Slides.

Detailed evaluation of prostate cancer glands is an essential yet labor-intensive step in grading prostate cancer. Gland segmentation can serve as a valuable preliminary step for machine-learning-based downstream tasks, such as Gleason grading, patient classification, cancer biomarker building, and survival analysis. Despite its importance, there is currently a lack of a reliable gland segmentation model for prostate cancer.

Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups.

Nanobodies, or single-domain antibody fragments, are promising candidates for molecular imaging due to their small size, rapid tissue penetration, and high target specificity. However, a significant challenge in their use is high renal uptake and retention, which can limit the therapeutic efficacy and complicate image interpretation. This study compares five different fluorine-18-labeled prosthetic groups for nanobodies, aiming to optimize pharmacokinetics and minimize kidney retention while maintaining tumor targeting.